ZW 1528
Alternative Names: ZW-1528Latest Information Update: 21 Jan 2025
Price :
$50 *
At a glance
- Originator Zymeworks
- Class Anti-inflammatories; Bispecific antibodies
- Mechanism of Action Interleukin 4 receptor alpha subunit antagonists; Interleukin 4 receptor antagonists; Interleukin-33 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Chronic obstructive pulmonary disease
Most Recent Events
- 16 Dec 2024 Preclinical trials in Chronic obstructive pulmonary disease in Canada (Parenteral) before December 2024 (Zymeworks pipeline, December 2024)
- 12 Dec 2024 Zymeworks expects to file an IND and non-U.S. applications in 2H-2026
- 12 Dec 2024 Zymeworks expects to commence phase I clinical studies in Cancer